THE NATIONAL RESEARCH AND INNOVATION AGENCY
As the only research institution in Indonesia, the National Research and Innovation Agency (BRIN) has launched 7 research and innovation funding schemes, one of which is the facilitation for health innovation product testing (PPIK). In 2022, after going through the selection process, BRIN will announce 3 candidates to receive PPIK facilitation.
Jakarta, 14 March 2022. BRIN announced 3 candidates for the facilitation of Health Innovation Product Testing (PPIK). The announcement will be made officially at WALIDASI (Webinar on Research and Innovation Facilitation and Funding), on Tuesday (15/03) virtually. PPIK facilitation is one of seven funding schemes launched by BRIN, namely 1) Facilitation of Sailing Day for years 2022 – 2024; 2) Research-Based Startup Company Funding; 3) Flagship for National Research Priority (PRN) of the National Research and Innovation Agency for 2022-2024; 4) Funding for Research on Handling of Coronavirus Disease 2019 (COVID-19); 5) Facilitation of Research Collaboration Centers; 6) Expedition and Exploration Funding for years 2022 – 2024; and 7) Facilitation of Health Innovation Product Testing (PPIK).
This PPIK funding facilitation is one of BRIN’s commitments to testing health innovation products in clinical trials that require large budget. Not only does it require large budget, the clinical trial process is also complex involving various parties such as regulators, industries, researchers, hospitals, and testing laboratories.
The three candidates who will receive PPIK in Stage I year 2022 are:
1) I Nyoman Jujur from the Nanotechnology and Materials RO – Advanced Materials Research Center, in collaboration with PT. Zenith Allmar. The candidate will develop the Prototype of Spine Implant which is one of products in the National Research Priority (PRN) activity;
2) Erry Dwi Kurniawan from the Electronics & Informatics RO – Telecommunication Research Center, in collaboration with PT. Tesena Inovindo. The candidate will develop CPAP-BiPAP Ventilators;
3) Zullies Ikawati from Gadjah Mada University in collaboration with PT. Konimex. The candidate will develop a Phytopharmaca Drug Candidate for Cognitive Enhancer from Secang Wood Extract.
Head of BRIN, Laksana Tri Handoko, said that high probability of product testing failure is the reason why the innovations of Indonesian researchers cannot be utilized properly. “Not only related to financing, the implementation of testing health innovation products has a high risk of failure. The obstacles in the implementation of health innovation product testing include among others time uncertainty, high costs of research on drugs, traditional medicines, vaccines, and facilities for testing health innovation products, and low success rate of clinical trials. These are the causes why the results of innovation of the nation’s men and women cannot yet be utilized by the community widely,” said Handoko.
According to him, this condition is a challenge for researchers who want their research results to be clinically tested and the industries that want to conduct clinical trials for their health innovation products. In response to this challenge, BRIN takes a role in assuming some of these risks in the form of providing PPIK facilitation funds.
In addition, since the Covid-19 pandemic, research on health innovation product testing related to pharmaceuticals (drugs, traditional/herbal medicines, or other pharmaceutical products) for treatment of or complementary to Covid-19 has significant increased. “From 2018 to 2020, the number of drug clinical trials approved by the Drug and Food Control Agency (BPOM) increased significantly, from 5 to 31 clinical trials or an increase by 520 percent,” he added.
“The same is the case for traditional medicine (OT) clinical trials. From 2019 to 2021, the number of OT clinical trials increased, from 13 to 30 clinical trials, or an increase by 230.8 percent,” he added.
Handoko said, PPIK facilitation is expected to inspire and motivate other researchers who still have problems in testing health innovation products, such as administrative arrangements, time and cost for carrying out research on drug innovation products, traditional medicines, vaccines, and medical devices. “These problems certainly result in the widespread use of research results by the public,” he said.
In addition, Handoko added, this facilitation is expected to accelerate testing of health products that are scientifically proven, safe, and passed tests at the human level. “This PPIK facilitation program also involves related industrial partners so that they are able to oversee the management of distribution and production permits as well as commercialization of the tested health products,” he concluded.